Recombinant Mouse CD267/TNFRSF13B Protein, N-His

Description of Recombinant Mouse CD267/TNFRSF13B Protein, N-His

Recombinant Mouse CD267/TNFRSF13B Protein, also known as B-cell maturation antigen (BCMA), is a type III transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. It is primarily expressed on the surface of B cells and plays a crucial role in regulating B cell survival and differentiation. Recombinant Mouse CD267/TNFRSF13B Protein is a valuable tool for research in immunology and cancer biology, and has potential therapeutic applications in various diseases.

Recombinant Mouse CD267/TNFRSF13B Protein is a 184 amino acid protein with a predicted molecular weight of approximately 21 kDa. It consists of a signal peptide, a cysteine-rich domain, four extracellular cysteine-rich repeats, a transmembrane domain, and a cytoplasmic tail. The extracellular domain of Recombinant Mouse CD267/TNFRSF13B Protein contains the binding site for its ligand, B-cell activating factor (BAFF), and its homolog, a proliferation-inducing ligand (APRIL).

The crystal structure of Recombinant Mouse CD267/TNFRSF13B Protein has been determined, revealing a trimeric assembly of the extracellular domain. The trimeric structure is essential for ligand binding and signal transduction. The cytoplasmic tail of Recombinant Mouse CD267/TNFRSF13B Protein contains a conserved death domain, which is crucial for activating downstream signaling pathways.

Recombinant Mouse CD267/TNFRSF13B Protein is a key regulator of B cell function and survival. Its main function is to bind to BAFF and APRIL, which are essential factors for B cell development and maturation. By binding to these ligands, Recombinant Mouse CD267/TNFRSF13B Protein activates signaling pathways that promote B cell survival and proliferation. It also plays a role in regulating the production of antibodies by B cells.

In addition to its role in B cell biology, Recombinant Mouse CD267/TNFRSF13B Protein has been implicated in the pathogenesis of various diseases. It has been shown to be overexpressed in multiple myeloma, a type of blood cancer, and may contribute to the survival and growth of cancer cells. Recombinant Mouse CD267/TNFRSF13B Protein has also been linked to autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, as well as inflammatory conditions like multiple sclerosis and inflammatory bowel disease.

Recombinant Mouse CD267/TNFRSF13B Protein has a wide range of applications in both research and therapeutic settings. In research, it is commonly used as a tool to study B cell biology, including B cell survival, proliferation, and antibody production. It is also used to investigate the role of Recombinant Mouse CD267/TNFRSF13B Protein in diseases such as cancer and autoimmune disorders.

In the field of therapeutics, Recombinant Mouse CD267/TNFRSF13B Protein has shown promise as a potential target for the treatment of various diseases. Several monoclonal antibodies targeting Recombinant Mouse CD267/TNFRSF13B Protein have been developed and are currently being evaluated in clinical trials for the treatment of multiple myeloma and other B cell malignancies. In addition, Recombinant Mouse CD267/TNFRSF13B Protein has been identified as a potential target for the treatment of autoimmune diseases, and drugs targeting this protein are currently in development.

In conclusion, Recombinant Mouse CD267/TNFRSF13B Protein